Leukemia & Lymphoma

Article	Citations
Prognostic significance of blast immunophenotype on first post-induction bone marrow biopsy	75
A phase II study to evaluate the efficacy of low-dose rasburicase (1.5mg) in adolescent and adult acute leukemia and high-grade lymphomas with tumor lysis syndrome	39
Chronic lymphocytic leukemia transdifferentiated to blastic neoplasm with T/plasmacytoid dendritic cell immunophenotype	38
Brentuximab vedotin plus bendamustine versus platinum-based regimens as 1st salvage therapy and ‘bridge’ to autologous hematopoietic stem cell transplantation for relapsed/refractory Hodgkin lymphoma	34
Multicenter comparison of first salvage chemotherapy versus novel therapy regimens in adult relapsed/refractory acute lymphoblastic leukemia	31
Prognostic value of early imaging following CAR-T cell therapy in diffuse large B-cell lymphoma	29
Rituximab in combination with adapted-dose of ifosfamide and etoposide as salvage treatment in elderly refractory/relapsed diffuse large B-cell lymphoma patients non-candidate for high dose therapy: a	28
Efficacy and safety of voriconazole as invasive fungal infection prophylaxis in patients with acute myeloid leukemia	23
Presence of minimal residual disease determined by next-generation sequencing is not a reliable prognostic biomarker in children with acute lymphoblastic leukemia	22
Acute kidney injury in patients receiving high-dose etoposide phosphate as conditioning prior to hematopoietic stem cell transplantation in hematologic malignancies may be associated with elevated bod	22
Dose-adjusted direct oral anticoagulants (DOACs) in patients with acute leukemia: experience of a tertiary cancer care center	21
Evaluating early response assessment in extranodal natural killer/T-cell lymphoma by analyzing ΔSUVlbm between baseline and interim 18 F-FDG PET/CT scans	21
At least two high-risk cytogenetic abnormalities indicate the inferior outcomes for newly diagnosed multiple myeloma patients: a real-world study in China	20
Olaparib combined with low-dose chemotherapy for relapsed AML1::ETO positive acute myeloid leukemia in elderly patient	20
The promising outcome with simultaneous integrated boost intensity modulated radiotherapy in confined nasal extranodal NK/T-cell lymphoma	20
Avascular necrosis in older adolescents and adults with acute lymphoblastic leukemia treated with FRALLE protocols: a multicenter analysis of incidence, risk factors and morbidity	19
CD5+ diffuse large B-cell lymphoma: a narrative review	18
Pneumocystis jirovecii pneumonia with use of brentuximab vedotin in treatment-naïve Hodgkin lymphoma	18
Real world efficacy of luspatercept in patients with lower-risk myelodysplastic syndromes/neoplasms (MDS); a single center study in a heavily pretreated cohort	18
Ki67 proliferation index in follicular lymphoma is associated with favorable outcome in patients treated with R-CHOP	18
Deintensification of radiation dose to 20 Gy for conjunctival mucosa-associated lymphoid tissue (MALT) lymphoma	18
The quest for validated treatment endpoints in light chain (AL) amyloidosis: composite criteria for a composite disease	17
Post PARP inhibitor therapy-related acute megakaryoblastic leukemia in a patient with germline BRCA1-mutated high-grade serous ovarian carcinoma	17
Inotuzumab ozogamicin is deliverable in relapsed ALL patients with end-stage renal disease on hemodialysis	16
Comparative effectiveness of salvage chemotherapy regimens and chimeric antigen T-cell receptor therapies in relapsed and refractory diffuse large B cell lymphoma: a network meta-analysis of clinical	15

Comprehensive analysis of clinical, pathological, and molecular features in chronic myelomonocytic leukemia: frequent ASXL1 and NRAS mutat	15
Real-world evidence on the use of daratumumab, bortezomib and dexamethasone (DVd) in lenalidomide-refractory myeloma patients: subgroup analysis of the multicenter retrospective experience by “rete em	15
Evolution in the frontline treatment of patients with chronic lymphocytic leukemia: experience from one European center	15
Smoldering multiple myeloma: biology, clinical manifestations and management	15
Polatuzumab vedotin extravasation injury: a case report	15
Profound response to venetoclax monotherapy in a patient with BCL-2 positive relapsed multiple myeloma and extramedullary CNS manifestations	14
Thromboprophylaxis in multiple myeloma	14
Cognition in patients treated with targeted therapy for chronic myeloid leukemia: a controlled comparison	14
Optimal dosing of cytarabine in childhood acute myeloid leukemia: do we have the answer yet?	14
The landscape of clinical trials for heavily pretreated multiple myeloma: opportunity for more randomization?	14
Should WE use flow cytometry to assess bone marrow involvement by lymphoma?	14
Prognostic value of minimal residual disease among patients with classical Hodgkin lymphoma undergoing autologous stem cell transplantation	14
Transcriptional deregulation of LSD1 and LSD2 is associated with cytogenetic risk in chronic lymphocytic leukemia	14
Identification and genetic characterization of a NUP98-HHEX molecular rearrangement in a pediatric acute myeloid leukemia	13
Post-transplant maintenance therapy for MDS and AML: a bridge too far or the beginning of a new era?	13
Treatment of relapsed and refractory Waldenstrom Macroglobulinemia	13
Classic Hodgkin lymphoma cloaked in an intense sarcoid-like reaction	13
Uncommon histiocyte-rich pseudotumor after chemotherapy in peripheral T-cell lymphoma	13
Outcomes with allogeneic hematopoietic stem cell transplantation in TP53-mutated acute myeloid leukemia: a systematic review and meta-analysis	13
Discriminating between Waldenström macroglobulinemia and marginal zone lymphoma using logistic LASSO regression	13
Calcific tendinopathy: an unexpected side effect of tyrosine kinase inhibitor?	13
Management of relapsed/refractory mantle cell lymphoma	12
Solving coagulation conundrums: comparing prophylaxis strategies in adult patients receiving PEG-asparaginase	12
Real-world assessment of isocitrate dehydrogenase inhibitor-associated differentiation syndrome	12
Targets and treatments in primary CNS lymphoma	12
Weight-adjusted urinary creatinine excretion predicts transplant outcomes in adult patients with acute myeloid leukemia in complete remission	12
Incidence of major bleeding in patients with chronic lymphocytic leukemia receiving ibrutinib and therapeutic anticoagulation	12
The mechanism of action, pharmacological characteristics, and clinical utility of the amyloid depleter birtamimab for the potential treatment of AL amyloidosis	12
The impact of mild-to-moderate chronic kidney disease on hospitalization outcomes in patients with acute myeloid leukemia	12
Improvement in mortality of hospitalized patients with hematological malignancies in the 2nd wave of COVID-19 in the UK: experience of a large London NHS trust	12
Circulating serum microRNAs as biomarkers of drug resistance in multiple myeloma patients treated with bortezomib-based regimens – pilot study	11
Norovirus and sapovirus infections after allogeneic hematopoietic stem cell transplantation: is it worth it to look for them?	11
Prognostic significance of copy number gains of MYC detected by fluorescence in situ hybridization in large B-cell lymphoma	11
Response to ‘blast identification in cerebrospinal fluid specimens from patients with acute myeloid leukemia: laboratory perspectives’	11
Optimization of physician and specialty pharmacy clinical workflow in assessment of risk category and symptom burden in patients with myelofibrosis (MF)	11
Outcomes with HLA-matched unrelated donor versus haploidentical hematopoietic cell transplantation	11
Severe lympho-depletion, abrogated thymopoiesis and systemic EBV positive T-cell lymphoma of childhood, a case	11
Use of PD-1 blockade in refractory/relapsed natural killer T-cell lymphomas: a systematic review and synthesis of case reports	11
Safe administration of obinutuzumab to rituximab-intolerant patients	10
Risk factors for the development of orthostatic hypotension during autologous stem cell transplant in patients with multiple myeloma	10
Infusion of haploidentical NKG2D-CAR-TCD45RA- cells in two pediatric patients with advanced relapsed and refractory acute leukemia was safe but achieved no clinical benefits	10
Results with allo-SCT in patients with relapsed/refractory HL treated with anti-PD-1, a multicenter retrospective cohort study: subcommittee of transplantation and cellular therapy (GATMO-TC) of the A	10
Organ toxicities associated with chimeric antigen receptor T-cell therapy	10
Putting the brain into mantle cell lymphoma	10
Improving the outcomes of secondary CNS lymphoma with high-dose thiotepa, busulfan, melphalan, rituximab conditioning and autotransplant	10
Estimating the impact of early bendamustine failure on feasibility of subsequent CAR-T cell therapy in mantle cell lymphoma	10
Post CAR-T cytopenia: poorly understood and clinically challenging	10
JAK inhibition in myelofibrosis: how to sequence treatment in this new era of multiple options	10
Subcutaneous panniculitic-like T-cell lymphoma localized to a site of peginterferon alfa-2a administration	10
The clinical characteristics and prognosis of patients with primary plasma cell leukemia (pPCL) according to the new IMWG definition criteria	10

Patients with plasma cell disorders undergoing autologous stem cell transplant retain their humoral response to COVID-19 vaccination but falling titers emphasize the importance of re-vaccination	10
Smoldering multiple myeloma: Reviewing the rationale for intervention	10
Impact of light chain isotype on clinical features and outcomes in systemic AL amyloidosis	10
XX International workshop on chronic lymphocytic leukemia	10
Results from an open-label phase 2a study of cerdulatinib, a dual spleen tyrosine kinase/janus kinase inhibitor, in relapsed/refractory peripheral T-cell lymphoma	9
Phase 1/2 multicenter trial of acalabrutinib in Chinese patients with relapsed/refractory mantle cell lymphoma	9
Real-world outcomes of frontline venetoclax-based therapy in older adults with acute myeloid leukemia: an analysis utilizing EHR data	9
A novel murine syngeneic CD8 peripheral T-cell lymphoma model with preclinical applications	9
MDM2 antagonist improves therapeutic activity of azacitidine in myelodysplastic syndromes and chronic myelomonocytic leukemia	9
CD274 structural variants for guiding treatment with PD-1 blockade in a patient with relapsed/refractory chronic active EBV transformed to NK lymphoma	9
Therapeutic approaches for the management of higher risk myelodysplastic syndromes	9
Blinatumomab for the treatment of acute lymphoblastic leukemia in a real-world setting: clinical vignettes	9
Unusually indolent CML: a stable non-responder without complete cytogenetic remission for 30 years including 17 years on tyrosine kinase inhibitor therapy	9
Advances in the treatment of high burden Follicular lymphoma: a Comprehensive review	9
Long-term survival of NPM1 AML treated with intensive chemotherapy with extensive molecular data available	9
Pulmonary infections in patients with acute myeloid leukemia receiving frontline treatment with hypomethylating agents	9
FISH combined with RT-PCR facilitates classification of Chinese adult patients with B-other ALL through improved identification of ZNF384 rearrangement	9
Prognostic significance of chromosomal genomic array testing in adults with newly-diagnosed acute lymphoblastic leukemia	9
Impact of pre-infusion disease burden on outcomes in pediatric relapsed/refractory B-cell lymphoblastic leukemia following anti-CD19 CAR T-cell therapy	9
Increased incidence of Pegaspargase-induced hypertriglyceridemia and associated pancreatitis observed in the Hispanic adult patient population	9
Clinically appropriate dose reductions and interruptions do not compromise efficacy in patients receiving treatment with ibrutinib	9
COVID-19 in patients with chronic lymphocytic leukemia: a Moscow observational study	9
Consecutive day dosing of high-dose cytarabine consolidation over 3 days is resource-efficient and safe in older adult patients with acute myeloid leukemia	9
Increased early mortality after fludarabine and melphalan conditioning with peripheral blood grafts in haploidentical hematopoietic cell transplantation with post-transplant cyclophosphamide	9
Prognostic assessment value of immune escape-related genes in patients with acute myeloid leukemia	9
Dupilumab for the treatment of refractory lenalidomide rash in patients with multiple myeloma	9
Primary central nervous system lymphoma in children - a rare but serious disease with good prognosis from a single center in China	8
Comorbidities and socioeconomic status are predictors of survival in children and young adults with Burkitt lymphoma	8
Unmet needs in relapsed/refractory mantle cell lymphoma (r/r MCL) post-covalent Bruton tyrosine kinase inhibitor (BTKi): a systematic literature review and meta-analysis	8
Reliable IGHV status assessment by next generation sequencing in routine practice for chronic lymphocytic leukemia	8
Matching adjusted indirect comparisons of efficacy outcomes for idecabtagene vicleucel (ide-cel, bb2121) versus selinexor + dexamethasone and belantamab mafodotin in relapsed and refractory multiple m	8
Progressive multifocal leukoencephalopathy post ibrutinib therapy in relapsed chronic lymphocytic leukaemia	8
A new scoring system to predict survival in elderly advanced stage Hodgkin lymphoma patients	8
Association of the pre-transplant CD4/CD8 ratio with the prognosis following allogeneic hematopoietic stem cell transplantation	8
The prognostic role of gene polymorphisms in patients with indolent non-Hodgkin lymphomas and mantle-cell lymphoma receiving bendamustine and rituximab: results of the 5-year follow-up study	8
Fish evaluation of additional cytogenetic aberrations and hyperdiploidy in childhood Burkitt lymphoma	8
Transplantation provides superior survival high risk myeloid malignancies in older patients	8
Flow cytometry is a sensitive technique to assess marrow involvement by B cell non-Hodgkins lymphoma	8
Radiation therapy for the management of T cell cutaneous lymphomas. Updated results of the role of low dose total skin electron beam (TSEB) therapy	8
TP53/PLCG2-mutated diffuse large B-cell lymphoma richter transformation (DLBCL-RT) of CLL with unusual CD2 and PD-1 expression	8
IDH2 mutations in acute myeloid leukemia	8
Genomic landscape of myelodysplastic/myeloproliferative neoplasm can predict response to hypomethylating agent therapy	8
Recent advances in the treatment of polycythemia vera	8
Apparent coexistence of ETV6::RUNX1 and KMT2A::MLLT3 fusions due to a nonproductive KMT2A rearrangement in B-ALL	8
Preclinical activity of a novel multi-axis inhibitor in aggressive and indolent B-cell malignancies	8
What is the optimal time to initiate hypomethylating agents (HMAs) in higher risk myelodysplastic syndromes (MDSs)?	8
Idarubicin and cytarabine with and without midostaurin for FLT3-mutated acute myeloid leukemia	8
Characteristics, treatment, and outcomes of mantle cell lymphoma with cutaneous involvement: a decade-long study at MD Anderson cancer center	8
Impact of adherence to ibrutinib on clinical outcomes in real-world patients with chronic lymphocytic leukemia	8
Targeting MALT1 for the treatment of diffuse large B-cell lymphoma	8
High-dose methotrexate dosing strategy in primary central nervous system lymphoma	8
Role of high acquisition flow cytometry in the detection of marrow involvement in patients with extramedullary B cell non-Hodgkins lymphoma: a comparison with marrow aspirate cytology, trephine biopsy	8
Relationship between uric acid and kidney function in adults at risk for tumor lysis syndrome	8
Asparaginase therapy in patients with acute lymphoblastic leukemia: expert opinion on use and toxicity management	8
Prognostic significance of NOTCH1/FBXW7 mutations in pediatric T cell acute lymphoblastic leukemia: a study of minimal residual disease risk-directed CCLG-ALL 2008 treatment protocol	7
NK- and T-cell lymphoma of the nasal cavity and paranasal sinuses in Denmark 1980–2017: a nationwide cohort study	7
The prognostic role of NKG2A expression for patients with chronic myeloid leukemia after treatment discontinuation	7
High seroconversion rates amongst black and Hispanics with hematologic malignancies after SARS-CoV-2 vaccination	7
Patient characteristics, treatment patterns, and mortality in elderly patients newly diagnosed with acute myeloid leukemia meeting ineligibility criteria for high intensity chemotherapy	7
Venetoclax-based combinations in AML and high-risk MDS prior to and following allogeneic hematopoietic cell transplant	7
Molecular- and cytogenetic characterization of the IGH associated t(1;14) in a nodal marginal zone B-cell lymphoma case	7
Mutations known from B-cell lymphoid malignancies are not found in CD34 + stem cells from patients with lymphoma	7
Is acute lymphoblastic leukemia with mature B-cell phenotype and KMT2A rearrangements a new entity? A systematic review and meta-analysis	7
MRD dynamics during maintenance therapy in 259 patients with nontransplant eligible multiple myeloma	7
Comparative analysis of infectious complications with outpatient vs. inpatient care for adults with high-risk myeloid neoplasm receiving intensive induction chemotherapy	7
Prolonged Epstein-Barr virus reactivation coincident with chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation	7
Whole-genome sequencing as an alternative to analyze copy number abnormalities in acute myeloid leukemia and myelodysplastic syndrome	7
Ruxolitinib bridging therapy to allogeneic SCT for high-risk refractory subcutaneous panniculitis-like T-cell lymphoma	7
Cytogenetic abnormalities in NPM1-mutated acute myeloid leukemia	7
Impact of SF3B1 mutation in myelofibrosis	7
Genetic profile of primary plasma cell leukemia in Korea: comparison with plasma cell myeloma	7
Prognostic value of presalvage metabolic tumor volume in patients with relapsed/refractory diffuse large B-cell lymphoma	7
Efficacy of lenalidomide in a patient with systemic mastocytosis associated with SF3B1 -mutant myelodysplastic syndrome	7
Shift in first-line therapies for United States Veterans Affairs (VA) patients with chronic lymphocytic leukemia (CLL)	7
Successful pregnancy outcome in a patient with myelofibrosis receiving ruxolitinib treatment in the first trimester	7
Prognostic significance of TIM-3 expression pattern at diagnosis in patients with t(8;21) acute myeloid leukemia	7
Clinical entity of cytomegalovirus disease in patients with malignant lymphoma on bendamustine therapy: a single-institution experience	7
Phase 1b, open-label study evaluating the safety and pharmacokinetics of atezolizumab (anti–PD-L1 antibody) administered in combination with Hu5F9-G4 to patients with relapsed and/or refractory acute	7
Pembrolizumab for myelodysplastic syndromes after failure of hypomethylating agents in the phase 1b KEYNOTE-013 study	7
CD19 expression is maintained in DLBCL patients after treatment with tafasitamab plus lenalidomide in the L-MIND study	7

BCL2 translocation in high grade B cell lymphoma (NOS, DH/TH) is associated with reduced progression free survival	7
Proteomic analysis in diffuse large B-cell lymphoma identifies dysregulated tumor microenvironment proteins in non-GCB/ABC subtype patients	7
Frequency of infusion-related reactions with CPX-351 treatment in an observational study in adults with newly diagnosed therapy-related AML or AML with myelodysplasia-related changes (AML-MRC)	7
Risk of SARS-CoV-2 infection and severe COVID-19 in hematological patients who received or not pre-exposure prophylaxis with tixagevimab/cilgavimab: a target trial emulation	7
A 10-color flow cytometry panel for diagnosis and minimal residual disease in chronic lymphocytic leukemia	7
Embelin inhibits viability of cutaneous T cell lymphoma cell lines HuT78 and H9 by targeting inhibitors of apoptosis	6
Real-world associations of cytokine release syndrome and neurotoxicity with efficacy in patients receiving anti-CD-19 chimeric antigen receptor T-cell therapy for large B-cell lymphoma: the Mayo Clini	6
What constitutes meaningful improvement in myelodysplastic syndromes?	6
A retrospective analysis of factors impacting survival in United States military veterans with multiple myeloma	6
Treatment patterns, resource utilization and clinical outcomes in patients with higher risk myelodysplastic syndromes (MDS) in United States community practices	6
RAISING revealed a heterogenous pattern of HTLV-1 clonality after HLA-haploidentical peripheral blood stem cell transplantation for ATL	6
Integrated genomic and single-cell transcriptomic analyses reveal clonal evolution and immune signature in donor cell leukemia after haploidentical allogeneic hematopoietic stem cell transplantation	6
Expression of TCF3 target genes defines a subclass of diffuse large B-cell lymphoma characterized by up-regulation of MYC target genes and poor clinical outcome following R-CHOP therapy	6
PET-CR as a potential surrogate endpoint in untreated DLBCL: meta-analysis and implications for clinical trial design	6
The effect of the plasma methotrexate concentration during high-dose methotrexate therapy in childhood acute lymphoblastic leukemia	6
Population-level impact of ibrutinib for chronic lymphocytic leukemia in British Columbia, Canada	6
Characteristics and clinical correlation of TIM-3 and PD-1/PD-L1 expressions in leukemic cells and tumor microenvironment in newly diagnosed acute myeloid leukemia	6
Treatment of relapsed or refractory FLT-3 acute myelogenous leukemia with a triplet regimen of hypomethylating agent, venetoclax, and gilteritinib	6
Improved survival after allogeneic transplantation for acute lymphoblastic leukemia in adults: a Danish population-based study	6
Epidemiology and survival of primary extraosseous plasmacytoma: insights from a population-based study with a 20-year follow-up	6
CRLF2 and IKZF1 abnormalities in childhood hematological malignancies other than B-cell Acute Lymphoblastic Leukemia	6
Mature T-cell and NK-cell lymphoma involvement of the central nervous system: a single center experience	6
Cytarabine dose intensification improves survival in older patients with secondary/high-risk acute myeloid leukemia in matched real-world versus clinical trial data	6
Phase 2 trial of umbralisib, ublituximab, and venetoclax in patients with relapsed/refractory mantle cell lymphoma	6
Clinical utility of interim CT scans in patients receiving chemoimmuntherapy for first line treatment of follicular lymphoma	6
CD38 as a multifaceted immunotherapeutic target in CLL	6
Impact of diet and antibiotics on gut microbiota and outcomes in patients with multiple myeloma treated with autologous hematopoietic stem cell transplantation	6
Cost-effectiveness of adding quizartinib to induction chemotherapy for patients with FLT3- mutant acute myeloid leukemia	6
Clinico-genomic profiling and clonal dynamic modeling of TP53-aberrant myelodysplastic syndrome and acute myeloid leukemia	6
The pretreatment Controlling Nutritional Status score is an independent prognostic factor in elderly patients with diffuse large B-cell lymphoma	6
Dermatologic adverse events in acute lymphocytic leukemia patients treated with bispecific T-cell engager blinatumomab	6
The inherited genetic contribution and polygenic risk score for risk of CLL and MBL: a narrative review	6
Successful treatment with bortezomib, thalidomide and dexamethasone in plasma cell myeloma post-bone marrow transplant	6
Breakthrough COVID-19 is mild in vaccinated patients with hematological malignancy receiving tixagevimab-cilgavimab as pre-exposure prophylaxis	6
The NOTCH1 and miR-34a signaling network is affected by TP53 alterations in CLL	6
CD69 marks a subpopulation of acute myeloid leukemia with enhanced colony forming capacity and a unique signaling activation state	6
Early CD49d downmodulation in chronic lymphocytic leukemia patients treated front-line with ibrutinib plus rituximab predicts long-term response	6
Targeting the immune microenvironment in mantle cell lymphoma: implications for current and emerging therapies	6
Disparity in treatment patterns among Medicare beneficiaries diagnosed with chronic lymphocytic leukemia: an analysis of patient and contextual factors	6
CD303 (BDCA-2) – a potential novel target for therapy in hematologic malignancies	5
An open-label phase 2 study treating patients with first or second relapse of multiple myeloma with carfilzomib, pomalidomide, and dexamethasone (KPd): SELECT study	5
Correction	5
A retrospective cohort study describing chemotherapy-induced peripheral neuropathy in Non-Hodgkin lymphoma patients treated with EPOCH ± R: does HIV status matter?	5
Prognostic significance of deep sequencing for analysis of measurable residual disease in acute myeloid leukemia with NPM1 mutation	5
Richter transformation to aggressive plasmablastic neoplasm related to selection of a BTK-mutated clone in a patient with CLL/SLL treated by ibrutinib	5
Neurotoxicity with blinatumomab in combination with intrathecal methotrexate therapy	5
Hyperleukocytosis associated with delayed presentation among patients with acute leukemia during the COVID-19 pandemic	5
Multi-site pre-therapeutic biopsies demonstrate genetic heterogeneity in patients with newly diagnosed diffuse large B-cell lymphoma	5
The potential for technology to aid quantitative assessment in cutaneous T cell lymphoma	5
Validation of SAPS 3 for predicting in-hospital mortality in patients with haematological malignancy requiring ICU management	5
Early cytopenias and infections following chimeric antigen receptor T-Cell therapy for hematologic malignancies	5
Time to omit interim CT imaging during frontline chemoimmunotherapy for patients with follicular lymphoma?	5
Value of measurable residual disease monitoring in patients with acute promyelocytic leukemia in the era of frontline ‘chemotherapy-free’ therapy	5
A phase 2 study of autologous stem cell transplantation as salvage therapy for older patients with aggressive B-cell lymphoma prospectively evaluated by comprehensive geriatric assessment: the FIL_REC	5
Correction	5
The value of bispecific antibodies in relapsed and refractory DLBCL	5
Imaging minimal residual disease evaluation in multiple myeloma using [ 18 F]FDG PET/MRI	5
CXCR4 expression of multiple myeloma as a dynamic process: influence of therapeutic agents	5
New therapies for angioimmunoblastic T-cell lymphoma: a comprehensive review and analysis	5
CD22 expression in acute myeloid leukemia: close correlation with interleukin-2 receptor α-chain (CD25) expression and poor prognosis	5
Phase 1b/2 study of ibrutinib and lenalidomide with dose-adjusted EPOCH-R in patients with relapsed/refractory diffuse large B-cell lymphoma*	5
Clinical characteristics and prognostic factors of 70 patients with Sézary syndrome: a single-institutional experience at Moffitt cancer center	5
Comparative efficacy and safety of tisagenlecleucel and axicabtagene ciloleucel among adults with r/r follicular lymphoma	5
Clinicoradiopathological correlation of symptomatic focal bone marrow lesions in Waldenström Macroglobulinaemia	5
Mast cell sarcoma transdifferentiated from clonally-related T-lymphoblastic leukemia upon acquisition of TP53 mutation and genetic complexity	5
Unmet need for mental health services in indolent lymphoma: age differences over one-year post-diagnosis	5
Innovative management of BK virus nephropathy post-HSCT: a case report and therapeutic insights	5
Exposure to phenoxyacetic acids and glyphosate as risk factors for non-Hodgkin lymphoma– pooled analysis of three Swedish case-control studies including the sub-type hairy cell leukemia	5
CDKN2A/B deletion as an independent negative prognostic factor for allogeneic hematopoietic stem cell transplantation in childhood B cell precursor acute lymphoblastic leukemia	5
A case report of solitary presentations of large B-cell lymphoma of immune-privileged sites (IP-LBCL) in the testis, vitreous body, and skin	5
High CD34 positive stem cell dosage improves thrombocyte recovery in obese myeloma patients undergoing autologous stem cell transplantation	5
Correction	5
Incidence of Pneumocystis jirovecii pneumonia (PJP) in patients receiving BTK inhibitors who did not receive PJP prophylaxis	5
Indolent B-cell non-Hodgkin lymphomas in children: high association with inborn errors of immunity	5
Treatment outcomes of venetoclax-combination regimens for relapsed/refractory myeloid malignancies after anti-CD47-directed therapy	5
Cyclin-dependent kinase-9 in B-cell malignancies: pathogenic role and therapeutic implications	5
Comparison of treatment-related and de novo CCUS: a retrospective analysis from two centers	5
Patient-reported outcomes from the phase 3 ADMIRAL trial in patients with FLT3-mutated relapsed/refractory AML	5
Momelotinib vs. ruxolitinib in myelofibrosis patient subgroups by baseline hemoglobin levels in the SIMPLIFY-1 trial	5
Response to everolimus in a patient with refractory HGBL-NOS harboring multiple genomic aberrations in PTEN	5
Correction	5
Daratumumab-based regimen for cold agglutinin disease refractory to therapy directing B-cell clone	5
Burkitt lymphoma in patients with chronic lymphocytic leukemia and other indolent B-cell lymphoid malignancies	5
Real-world treatment patterns for patients with newly diagnosed multiple myeloma in Alberta, Canada	5
The lymphocyte-to-monocyte ratio in follicular lymphoma	5
A combination of humanized anti-BCMA and murine anti-CD38 CAR-T cell therapy in patients with relapsed or refractory multiple myeloma	5
Influence of MTHFR C677T and A1298C polymorphisms on the survival of pediatric patients with non-Hodgkin lymphoma	5
African American and Caucasian patients with Sézary syndrome have no differences in outcomes at an ethnically diverse urban medical center	5
Evaluation of an interdisciplinary venetoclax initiation process in minimizing risk of tumor lysis syndrome	5
Outcomes after initial refusal of curative treatment in patients with classic Hodgkin lymphoma	5
Inhibitory effect of a neddylation blockade on HTLV-1-infected T cells via modulation of NF-κB, AP-1, and Akt signaling	5
Real-world treatment patterns, healthcare resource use, and costs among patients with diffuse large B-cell lymphoma: a retrospective analysis of US claims data	5
Adult T-cell leukemia-lymphoma with neurolymphomatosis successfully controlled by valemetostat: a case report and review of literature	5
Matching-adjusted indirect comparison of axi-cel and liso-cel in relapsed or refractory large B-cell lymphoma	5
Predicting relapse in acute lymphoblastic leukemia	5